{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:15:20Z","timestamp":1779887720402,"version":"3.53.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000093","name":"U.S. Department of Health & Human Services | NIH | Center for Information Technology","doi-asserted-by":"publisher","award":["HHSN272201600013C, AI134907, AI145617, UL1TR001439"],"award-info":[{"award-number":["HHSN272201600013C, AI134907, AI145617, UL1TR001439"]}],"id":[{"id":"10.13039\/100000093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The spread of the Omicron SARS-CoV-2 variant underscores the importance of analyzing the cross-protection from previous non-Omicron infection. We have\u00a0developed a high-throughput neutralization assay for Omicron SARS-CoV-2 by engineering the Omicron spike gene into an mNeonGreen USA-WA1\/2020 SARS-CoV-2 (isolated in January 2020). Using this assay, we determine the neutralization titers (defined as the maximal serum dilution that inhibited 50% of infectious virus) of patient sera collected at 1- or 6-months after infection with non-Omicron SARS-CoV-2. From 1- to 6-month post-infection, the neutralization titers against USA-WA1\/2020 decrease from 601 to 142 (a 4.2-fold reduction), while the neutralization titers against Omicron-spike SARS-CoV-2 remain low at 38 and 32, respectively. Thus, at 1- and 6-months after non-Omicron SARS-CoV-2 infection, the neutralization titers against Omicron are 15.8- and 4.4-fold lower than those against USA-WA1\/2020, respectively. The low cross-neutralization against Omicron from previous non-Omicron infection supports vaccination of formerly infected individuals to mitigate the health impact of the ongoing Omicron surge.<\/jats:p>","DOI":"10.1038\/s41467-022-28544-w","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T06:04:57Z","timestamp":1644386697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection"],"prefix":"10.1038","volume":"13","author":[{"given":"Jing","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-7038","authenticated-orcid":false,"given":"Hongjie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-016X","authenticated-orcid":false,"given":"Xuping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitanya","family":"Kurhade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael R. G.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-8556","authenticated-orcid":false,"given":"Scott C.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-6667","authenticated-orcid":false,"given":"Ping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-1616","authenticated-orcid":false,"given":"Pei-Yong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"28544_CR1","doi-asserted-by":"publisher","unstructured":"Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature, https:\/\/doi.org\/10.1038\/s41586-020-2895-3 (2020).","DOI":"10.1038\/s41586-020-2895-3"},{"key":"28544_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"28544_CR3","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. Nature, In press, https:\/\/doi.org\/10.1101\/2021.03.08.434499 (2021).","DOI":"10.1101\/2021.03.08.434499"},{"key":"28544_CR4","unstructured":"WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (2021)."},{"key":"28544_CR5","unstructured":"UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical brief 31 (2021)."},{"key":"28544_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"28544_CR7","doi-asserted-by":"publisher","unstructured":"Ku, Z. et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nat. Commun., https:\/\/doi.org\/10.1038\/s41467-41020-20789-41467 (2021).","DOI":"10.1038\/s41467-41020-20789-41467"},{"key":"28544_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17892-0","volume":"11","author":"AE Muruato","year":"2020","unstructured":"Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat. Commun. 11, 4059 (2020).","journal-title":"Nat. Commun."},{"key":"28544_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848 e843 (2020).","journal-title":"Cell Host Microbe"},{"key":"28544_CR10","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","volume":"383","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson, D. F. et al. Humoral immune response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 383, 1724\u20131734 (2020).","journal-title":"N. Engl. J. Med."},{"key":"28544_CR11","doi-asserted-by":"publisher","unstructured":"Falsey, A. R. et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N. Engl. J. Med., https:\/\/doi.org\/10.1056\/NEJMc2113468 (2021).","DOI":"10.1056\/NEJMc2113468"},{"key":"28544_CR12","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","volume":"2","author":"WN Chia","year":"2021","unstructured":"Chia, W. N. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe 2, e240\u2013e249 (2021).","journal-title":"Lancet Microbe"},{"key":"28544_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1056\/NEJMc2032195","volume":"384","author":"AT Widge","year":"2021","unstructured":"Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80\u201382 (2021).","journal-title":"N. Engl. J. Med."},{"key":"28544_CR14","doi-asserted-by":"publisher","unstructured":"Cele S. et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. MedRxiv, https:\/\/doi.org\/10.1101\/2021.12.08.21267417 (2021).","DOI":"10.1101\/2021.12.08.21267417"},{"key":"28544_CR15","doi-asserted-by":"publisher","unstructured":"Wilhelm A. et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. MedRiv, https:\/\/doi.org\/10.1101\/2021.12.07.21267432 (2021).","DOI":"10.1101\/2021.12.07.21267432"},{"key":"28544_CR16","doi-asserted-by":"publisher","unstructured":"Dejnirattisai W. et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum. MedRxiv, https:\/\/doi.org\/10.1101\/2021.12.10.21267534 (2021).","DOI":"10.1101\/2021.12.10.21267534"},{"key":"28544_CR17","unstructured":"Guardian, T. South Africa: previous infections may explain Omicron hospitalisation rate. https:\/\/www.theguardian.com\/world\/2021\/dec\/2014\/south-africa-previous-infections-may-explain-omicron-hospitalisation-rate?fr=operanews (2021)."},{"key":"28544_CR18","doi-asserted-by":"publisher","unstructured":"Redd A. D. et al. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. BioRxiv, https:\/\/doi.org\/10.1101\/2021.12.06.471446 (2021).","DOI":"10.1101\/2021.12.06.471446"},{"key":"28544_CR19","doi-asserted-by":"publisher","unstructured":"Gruell H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. MedRiv, https:\/\/doi.org\/10.1101\/2021.12.14.21267769 (2021).","DOI":"10.1101\/2021.12.14.21267769"},{"key":"28544_CR20","doi-asserted-by":"publisher","unstructured":"Xia, H. et al. Neutralization of Omicron SARS-CoV-2 by 2 or 3 doses of BNT162b2 vaccine. bioRxiv, https:\/\/doi.org\/10.1101\/2022.1101.1121.476344 (2022).","DOI":"10.1101\/2022.1101.1121.476344"},{"key":"28544_CR21","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41596-021-00491-8","volume":"16","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Engineering SARS-CoV-2 using a reverse genetic system. Nat. Protoc. 16, 1761\u20131784 (2021).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28544-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28544-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28544-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:09:25Z","timestamp":1669288165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-28544-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["28544"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-28544-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.20.473584","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare competing interests. X.X. and P.-Y.S. have filed a patent on the reverse genetic system. J.Z., H.X., X.X., and P.-Y.S. received compensation from Pfizer for COVID-19 vaccine development. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"852"}}